Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +45

Resources Management Corp CT ADV Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat

AI-generated analysis

πŸ“‰ Resources Management Corp CT ADV lowered its Gilead stake by 48.6% in Q4, selling 19,260 shares to end with a $2.5 million position.

πŸ“ˆ Gilead beat quarterly earnings expectations with EPS of $2.03 and revenue of $6.96 billion, surpassing analyst forecasts.

πŸ’° The company declared a quarterly dividend of $0.82 per share, yielding approximately 2.6% for shareholders of record on June 15th.

πŸ‘” Insiders including CFO Andrew D. Dickinson and CEO Daniel Patrick O'Day sold shares totaling $8.18 million over the last 90 days under pre-arranged plans.

🏦 Major institutional investors like Vanguard Group and State Street Corp increased their holdings in Gilead during the fourth quarter.

πŸ”¬ Positive catalysts include Phase 3 success for an oral HIV regimen and advancement of a Phase 2 study for denikitug in colorectal cancer.

πŸ“Š Analyst consensus rates Gilead as a 'Moderate Buy' with an average price target of $156.93, though some firms like Wall Street Zen downgraded the rating.

πŸ“‰ Technical indicators show short-term pressure as the stock has pulled back from its 50-day and 200-day moving averages.

πŸ’΅ Gilead maintains a strong financial profile with a market cap of $155.93 billion, a PE ratio of 17.11, and a debt-to-equity ratio of 0.89.

Bullish Signals
  • Gilead reported EPS of $2.03, beating the consensus estimate of $1.91 by $0.12.
  • Revenue reached $6.96 billion, exceeding analyst expectations of $6.91 billion and growing 4.4% year-over-year.
  • Maxim Group upgraded Gilead from a 'hold' to a 'buy' rating with a $165.00 price target following positive Phase 3 HIV results.
  • Vanguard Group increased its stake by 1.8%, now holding over 121 million shares worth nearly $14.9 billion.
  • The company announced a quarterly dividend of $0.82 per share, providing a 2.6% yield to investors.
  • Gilead is advancing a Phase 2 study for denikitug in difficult-to-treat colorectal cancer, expanding oncology prospects.
  • Analysts forecast Gilead will post -$0.79 EPS for the current year, though this reflects broader sector loss expectations rather than company-specific weakness.
Risk Factors
  • Insiders including the CFO and CEO sold a combined total of 62,000 shares worth $8.18 million in the last 90 days.
  • The stock has pulled back from its 50-day and 200-day moving averages, indicating short-term technical weakness.
  • Wall Street Zen downgraded Gilead from a 'strong-buy' to a 'hold' rating in late May.
  • Erste Group slightly lowered its FY2026 earnings estimate, aligning with broader market loss expectations for the sector.
Full Analysis
Resources Management Corp CT ADV significantly reduced its stake in Gilead Sciences (GILD) by 48.6% in the fourth quarter, selling 19,260 shares and ending with a holding valued at approximately $2.5 million. This move contrasts with increased positions from major institutional investors like Vanguard Group, State Street Corp, and Norges Bank, which collectively raised their stakes during the same period. Gilead reported better-than-expected quarterly financial results with earnings per share (EPS) of $2.03 against a consensus estimate of $1.91, driven by revenue of $6.96 billion that exceeded expectations. The company also declared a quarterly dividend of $0.82 per share, payable on June 29th to shareholders of record on June 15th, offering a yield of roughly 2.6%. Recent insider activity includes sales by CFO Andrew D. Dickinson and CEO Daniel Patrick O'Day, totaling over $8 million in the last 90 days, though these were executed under pre-arranged Rule 10b5-1 trading plans. Analyst sentiment remains mixed but generally positive, with an average target price of $156.93 and a 'Moderate Buy' rating, while Wall Street firms like Maxim Group have upgraded the stock following positive Phase 3 results for their HIV regimen. The article highlights Gilead's strong balance sheet with a current ratio of 1.97 and a market cap of $155.93 billion. Key catalysts include advancing clinical trials for oncology prospects like denikitug in colorectal cancer and positive topline results for HIV therapies, alongside neutral-to-negative technical indicators as the stock pulls back from its moving averages.